161 related articles for article (PubMed ID: 38681206)
1. Validation of Core Ingredients and Molecular Mechanism of Cinobufotalin Injection Against Liver Cancer.
Chen S; Li M; Xue C; Zhou X; Wei J; Zheng L; Duan Y; Deng H; Tang F; Xiong W; Xiang B; Zhou M
Drug Des Devel Ther; 2024; 18():1321-1338. PubMed ID: 38681206
[TBL] [Abstract][Full Text] [Related]
2. Network Pharmacology Prediction: The Possible Mechanisms of Cinobufotalin against Osteosarcoma.
Chen R; Guan Z; Zhong X; Zhang W; Zhang Y
Comput Math Methods Med; 2022; 2022():3197402. PubMed ID: 35069780
[TBL] [Abstract][Full Text] [Related]
3. A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling.
Yang AL; Wu Q; Hu ZD; Wang SP; Tao YF; Wang AM; Sun YX; Li XL; Dai L; Zhang J
Toxicol Appl Pharmacol; 2021 Nov; 431():115739. PubMed ID: 34619160
[TBL] [Abstract][Full Text] [Related]
4. Cinobufagin Suppresses The Characteristics Of Osteosarcoma Cancer Cells By Inhibiting The IL-6-OPN-STAT3 Pathway.
Zhang C; Ma K; Li WY
Drug Des Devel Ther; 2019; 13():4075-4090. PubMed ID: 31824138
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical evaluation of cinobufotalin as a potential anti-lung cancer agent.
Kai S; Lu JH; Hui PP; Zhao H
Biochem Biophys Res Commun; 2014 Sep; 452(3):768-74. PubMed ID: 25201730
[TBL] [Abstract][Full Text] [Related]
6. Network pharmacological mechanism of Cinobufotalin against glioma.
Li C; Guo H; Wang C; Zhan W; Tan Q; Xie C; Sharma A; Sharma HS; Chen L; Zhang Z
Prog Brain Res; 2021; 265():119-137. PubMed ID: 34560920
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
[TBL] [Abstract][Full Text] [Related]
8. Network Pharmacology Study on the Pharmacological Mechanism of Cinobufotalin Injection against Lung Cancer.
Mao Y; Peng X; Xue P; Lu D; Li L; Zhu S
Evid Based Complement Alternat Med; 2020; 2020():1246742. PubMed ID: 32148531
[TBL] [Abstract][Full Text] [Related]
9. Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma.
Yin Y; Guo J; Teng F; Yu L; Jiang Y; Xie K; Jiang M; Fang J
Drug Des Devel Ther; 2019; 13():4173-4184. PubMed ID: 31849449
[TBL] [Abstract][Full Text] [Related]
10. Ventilagolin Suppresses Migration, Invasion and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells by Downregulating Pim-1.
Liu Y; Cheng DH; Lai KD; Su H; Lu GS; Wang L; Lv JH
Drug Des Devel Ther; 2021; 15():4885-4899. PubMed ID: 34880599
[TBL] [Abstract][Full Text] [Related]
11. Ceramide production mediates cinobufotalin-induced growth inhibition and apoptosis in cultured hepatocellular carcinoma cells.
Cheng L; Chen YZ; Peng Y; Yi N; Gu XS; Jin Y; Bai XM
Tumour Biol; 2015 Aug; 36(8):5763-71. PubMed ID: 25724183
[TBL] [Abstract][Full Text] [Related]
12. A Novel Tetramethylpyrazine Chalcone Hybrid- HCTMPPK, as a Potential Anti-Lung Cancer Agent by Downregulating MELK.
Ma Y; Cui Q; Zhu W; Wang M; Zhai L; Hu W; Liu D; Liu M; Li Y; Li M; Han W
Drug Des Devel Ther; 2024; 18():1531-1546. PubMed ID: 38737331
[TBL] [Abstract][Full Text] [Related]
13. Chamaejasmenin E from Stellera chamaejasme induces apoptosis of hepatocellular carcinoma cells by targeting c-Met in vitro and in vivo.
Yu XQ; Yan QL; Shen S; Cheng ZY; Huang XX; Yao GD; Song SJ
Bioorg Chem; 2022 Feb; 119():105509. PubMed ID: 34844768
[TBL] [Abstract][Full Text] [Related]
14. A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma.
Wang Y; Liu Y; Liu Y; Zhou W; Wang H; Wan G; Sun D; Zhang N; Wang Y
Int J Pharm; 2015 Apr; 483(1-2):89-100. PubMed ID: 25681730
[TBL] [Abstract][Full Text] [Related]
15. Melatonin Differentially Modulates NF-кB Expression in Breast and Liver Cancer Cells.
Colombo J; Jardim-Perassi BV; Ferreira JPS; Braga CZ; Sonehara NM; Júnior RP; Moschetta MG; Girol AP; Zuccari DAPC
Anticancer Agents Med Chem; 2018; 18(12):1688-1694. PubMed ID: 29384062
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and anti-tumor activities of carbamate derivatives of cinobufagin.
Zhou Y; Hou J; Long H; Zhang Z; Lei M; Wu W
Steroids; 2020 Dec; 164():108749. PubMed ID: 33065151
[TBL] [Abstract][Full Text] [Related]
18. Structural optimization and biological evaluation for novel artemisinin derivatives against liver and ovarian cancers.
Zhou Y; Li X; Chen K; Ba Q; Zhang X; Li J; Wang J; Wang H; Liu H
Eur J Med Chem; 2021 Feb; 211():113000. PubMed ID: 33261896
[TBL] [Abstract][Full Text] [Related]
19. Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression.
Lu Y; Feng Y; Li Z; Li J; Zhang H; Hu X; Jiang W; Shi T; Wang Z
Eur J Med Chem; 2022 Jan; 227():113908. PubMed ID: 34656900
[TBL] [Abstract][Full Text] [Related]
20. Discovery of an Orally Efficacious MYC Inhibitor for Liver Cancer Using a GNMT-Based High-Throughput Screening System and Structure-Activity Relationship Analysis.
Kant R; Yang MH; Tseng CH; Yen CH; Li WY; Tyan YC; Chen M; Tzeng CC; Chen WC; You K; Wang WC; Chen YL; Chen YA
J Med Chem; 2021 Jul; 64(13):8992-9009. PubMed ID: 34132534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
